At Exogenus Therapeutics, we strive to address unmet needs in the fields of regenerative medicine and inflammatory disorders.

Exo-101, our lead candidate, has been shown in vitro and in vivo to have regenerative, anti‑inflammatory and immunomodulatory properties. 

Part of Exo-101’s mechanism of action functions via the modulation of immune cells, namely macrophages. As shown by Cardoso et al., Exo-101 is capable of nudging macrophages toward an anti-inflammatory phenotype, with potential paracrine effects on local cells.

Macrophages play a critical role in a wide range of inflammatory and degenerative conditions. Their dysregulation can contribute to tissue damage, impaired repair processes and chronic inflammation. Inflammatory skin conditions, such as psoriasis and atopic dermatitis, are also associated with altered macrophage activity, influencing both disease severity and persistence. In addition, macrophages are involved in tissue remodelling and are closely linked to fibrotic changes across multiple organ systems.

Following our results in wound healing, supporting an effect via macrophages, showing that Exo-101 not only accelerated wound closure but also improved tissue remodeling, we recognized the broader therapeutic potential of Exo-101, extending beyond localized repair to immunomodulatory functions. With Exo-101, we aim to address the underlying immune dysregulation that contributes to chronic inflammation and tissue damage in an array of degenerative and inflammatory conditions.